1999PubMedRequires access

[The serum bactericidal activity of domestic fleroxacin and lomefloxacin].

Miao Zhao, Shan Jiang, Run-Xi Wang

Open publisher page 0 citations

Abstract

OBJECTIVE: To evaluate antibacterial activities in vivo and in vitro of fleroxacin and lomefloxacin. METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out. RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively. CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.

About this research paper

What this paper is about

OBJECTIVE: To evaluate antibacterial activities in vivo and in vitro of fleroxacin and lomefloxacin. METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out. RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively. CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To evaluate antibacterial activities in vivo and in vitro of fleroxacin and lomefloxacin. METHODS: Minimal inhibitory concentration (MIC) and serum bactericidal activity (SBA) domestic fleroxacin and lomefloxacin were determined by agar disk dilution method and microplate method respectively. A clinical observation of fleroxacin and lomefloxacin for treating acute bacillary dysentery was carried out. RESULTS: MIC(90) of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae, S. aureus was 0.25-2 mg/L, being the same as that of ofloxacin. However, MIC(90) of lomefloxacin against the above mentioned species was twice or fourfold as that of ofloxacin and fleroxacin. The percent age of peak SBA > or = 1:8 with ofloxacin, fleroxacin and lomefloxacin against E. coli, K. pneumoniae, S. dysenteriae was 80%-100%, 90%-100% and 50%-80% respectively (P < 0.01). The clinical cure rates of acute bacillary dysentery were 93.3%, 100% and 100% and the bacterial clearance rates were 93.3%, 100% and 100% in the lomefloxacin, fleroxacin and ofloxacin group respectively. CONCLUSION: The antibacterial activity in vivo and in vitro of fleroxacin against E. coli, K. pneumoniae, S. dysenteriae was similar to that of ofloxacin and stronger than that of lomefloxacin.

Key concepts: Fleroxacin, Lomefloxacin, Ofloxacin, Medicine, Microbiology, Ciprofloxacin, Antibiotics, Biology

Related papers

Back to paper searchBrowse research topicsOriginal source
[The serum bactericidal activity of domestic fleroxacin and lomefloxacin]. — Research Paper | ScholarLens